Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Inovio Pharmaceuticals Inc
INO
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.8698
-0.0273
-3.04%
Ult. Agg.: Oct 26, 7:58 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Inovio Pharmaceuticals Financials
Inovio Pharmaceuticals (INO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.22) by 68.18 percent. This is a 88.52 percent increase over losses of $(0.61) per share
Benzinga Newsdesk
PRO
Inovio Pharmaceuticals Q1 EPS $(0.28) Beats $(0.36) Estimate, Sales $0.000 Miss $250.000K Estimate
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
INOVIO Pharmaceuticals Estimates Its Current Cash, Cash Equivalents And Short-Term Investments Balances To Support The Company's Operations Into Q4 2026; Projection Includes An Operational Net Cash Burn Estimate Of ~$22M For Q1 2026.
Benzinga Newsdesk
PRO
Inovio Pharmaceuticals Q4 EPS $(0.26) Beats $(0.38) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.38) by 31.22 percent. This is a 60 percent increase over losses of $(0.65) per share
Benzinga Newsdesk
Earnings Scheduled For March 12, 2026
Benzinga Insights
